SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications: D3S‑003 —...
Hence then, the article about d3 bio receives u s fda clearance for two ind applications enabling phase 1 trial of d3s 003 and phase 2 combination study of elisrasib d3s 001 with d3s 002 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002 )
Also on site :
- FIFA’s plan to raise billions from investors is sparking a backlash—one insider says Europe is angry because it could change soccer’s balance of power
- Monroe County committees vote to accept $160,000 Operation Stonegarden border security grant despite opposition
- Doc Talk Podcast: Director Sara Dosa On Her Oscar Contender ‘Time And Water’, Elegy For Iceland’s Disappearing Ice